Opthea Limited (OPT) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है South Yarra, VIC, Australia. वर्तमान CEO हैं Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,.
OPT के पास है IPO तिथि 2020-10-16, 33 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $4.24B.
Opthea Limited is a clinical-stage biopharmaceutical company based in South Yarra, Australia, focused on developing therapies for eye diseases. The company's pipeline is built on intellectual property targeting VEGF-C, VEGF-D, and VEGF Receptor-3 to address conditions involving abnormal blood and lymphatic vessel growth and vascular leakage. Its lead candidate, OPT-302, is a soluble VEGFR-3 inhibitor in clinical development for wet age-related macular degeneration and diabetic macular edema, designed to work alongside VEGF-A inhibitors for improved efficacy in retinal diseases.
